KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBIT: 2017-2025

Historic EBIT for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -$11.5 million.

  • Aquestive Therapeutics' EBIT fell 38.47% to -$11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.8 million, marking a year-over-year decrease of 164.37%. This contributed to the annual value of -$30.8 million for FY2024, which is 103.75% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' EBIT is -$11.5 million, which was down 0.98% from -$11.4 million recorded in Q2 2025.
  • Aquestive Therapeutics' EBIT's 5-year high stood at $55,000 during Q2 2024, with a 5-year trough of -$19.4 million in Q1 2025.
  • In the last 3 years, Aquestive Therapeutics' EBIT had a median value of -$8.3 million in 2024 and averaged -$8.0 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' EBIT skyrocketed by 101.31% in 2024, and later slumped by 20,769.09% in 2025.
  • Aquestive Therapeutics' EBIT (Quarterly) stood at -$11.7 million in 2021, then rose by 8.19% to -$10.7 million in 2022, then skyrocketed by 63.49% to -$3.9 million in 2023, then plummeted by 247.20% to -$13.6 million in 2024, then crashed by 38.47% to -$11.5 million in 2025.
  • Its EBIT stands at -$11.5 million for Q3 2025, versus -$11.4 million for Q2 2025 and -$19.4 million for Q1 2025.